HIM
RYTM icon

Hillsdale Investment Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

Hillsdale Investment Management’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.5M Sell
40,300
-2,000
-5% -$194K 0.1% 255
2025
Q4 		$4.53M Sell
42,300
-300
-0.7% -$31.8K 0.13% 223
2025
Q3 		$4.3M Buy
+42,600
New +$3.95M 0.13% 225
2018
Q3 		– Sell
-2,400
Closed -$75K – 540
2018
Q2 		$75K Buy
+2,400
New +$65.6K 0.01% 304

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Hillsdale Investment Management's RYTM Position: Q1 2026 in Review

Hillsdale Investment Management reduced its Rhythm Pharmaceuticals (RYTM) stake by 4.7% in Q1 2026, selling an estimated $194K and leaving 40,300 shares worth $3.5M. The position accounts for 0.1% of the portfolio, ranked #255.

Hillsdale Investment Management first reported a position in RYTM in Q2 2018 and has held it in 4 quarters since. The position peaked at $4.53M in Q4 2025. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

  • Hillsdale Investment Management held 40,300 shares of Rhythm Pharmaceuticals worth $3.5M as of Q1 2026.
  • Hillsdale Investment Management sold 2,000 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $194K.
  • Rhythm Pharmaceuticals made up 0.1% of Hillsdale Investment Management's portfolio in Q1 2026, its #255 holding.
  • Hillsdale Investment Management first reported a position in Rhythm Pharmaceuticals in Q2 2018 and has held it in 4 quarters since.
  • Hillsdale Investment Management's Rhythm Pharmaceuticals position peaked at $4.53M in Q4 2025.
  • 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on Hillsdale Investment Management's 13F filing for Q1 2026, filed 4 May 2026.